Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-week, open label, parallel group, multicentre, phase III, randomised controlled trial to compare the efficacy and safety of salbutamol metered dose inhaler taken as required for relief of symptoms, and budesonide/formoterol Turbuhaler taken as required for relief of symptoms, and regular budesonide Turbuhaler plus salbutamol metered dose inhaler taken as required for relief of symptoms, in adult patients with asthma

Next Previous
Trial Profile

A 52-week, open label, parallel group, multicentre, phase III, randomised controlled trial to compare the efficacy and safety of salbutamol metered dose inhaler taken as required for relief of symptoms, and budesonide/formoterol Turbuhaler taken as required for relief of symptoms, and regular budesonide Turbuhaler plus salbutamol metered dose inhaler taken as required for relief of symptoms, in adult patients with asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Budesonide; Salbutamol
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms Novel START

Most Recent Events

  • 06 Aug 2021 Results of a pooled analysis predicting asthma attacks based on the blood eosinophil count and exhaled nitric oxide from following clinical studies: Novel START, CAPTAIN, QUEST, Benralizumab Phase 2b, PATHWAY, STRATOS 1 & 2 and DREAM using biomarker-stratified trial-level attack rates published in the Thorax
  • 20 May 2020 Results (n=74) of a qualitative analysis exploring mild asthma patients assessing experiences of using one of two different preventer regimens presented at the 116th International Conference of the American Thoracic Society
  • 23 May 2019 Results published in the New England Journal of Medicine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top